Tepotinib (EMD 1214063)
For research use only. Not for use in humans.
Catalog No.S7067 Synonyms: MSC2156119
Molecular Weight(MW): 492.57
Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Phase 1.
Selleck's Tepotinib (EMD 1214063) has been cited by 6 publications
3 Customer Reviews
Ectopic expression of a RNAi-resistant SMARCE1 cDNA resensitizes SMARCE1-knockdown cells to MET inhibition in MET-amplified NSCLC cells. The above-described cells were grown in the absence or presence of 300 nM Crizotinib, 150 nM EMD1214063, or 150 nM PHA665752. Cells were then fixed, stained and photographed after 12 days (untreated) or 28 days (treated).
Cell Research, 2015, 25: 445-458. Tepotinib (EMD 1214063) purchased from Selleck.
HCC827 and PC9 cells cultured with CAF-CM were treated with c-met inhibitor Tepotinib (100 nM) or/and IGF1R inhibitor NVP-AEW541 (2 μM), protein expression was determined by western blot. *P<0.05
Biochim Biophys Acta Mol Basis Dis, 2018, 1864(3):793-803. Tepotinib (EMD 1214063) purchased from Selleck.
Anti-viral activity of the kinase inhibitor EMD 1214063. (A) Inhibition of different viruses with EMD 1214063. Monolayers of A549 cells were pre-treated with the indicated concentration of EMD 1214063 for 30 min, followed by infection with the different viruses (MOI = 0.3) in presence of drug. After 1 h, cells were washed with medium containing 20 mM ammonium chloride. Infection o 1212 f rLCMV-LASVGP and LCMV were detected after 16 h by IFA as in (2B). IAV infection was assessed after 6 h by staining for IAV N protein, whereas AdV was detected via its EGFP reporter in direct fluorescence after 24 h (means + SD, n = 3). (B) Representative images of inhibition experiments. LCMV and IAV antigens are in red, EGFP in green, nuclei are stained with DAPI (blue), bar = 100 μM. (C) Anti-viral effect of EMD 1214063 in primary human respiratory epithelial cells. Monolayers of primary human bronchiolar epithelial cells isolated from human bronchi were cultured in M96 plates for four days to obtain closed monolayers. Cells were pre-treated with the indicated concentration of EMD 1214063 for 30 min, followed by infection with rLCMV-LASVGP (LASV) and rLCMV-VSVG (VSV) at 1000 PFU/well for 1 h. Cells were washed and infection detected by IFA after 16 hours as in (2B). Data are means + SD, n = 3.
J Virol, 2016, 90(14):6412-29. . Tepotinib (EMD 1214063) purchased from Selleck.
Purity & Quality Control
Choose Selective c-Met Inhibitors
|Description||Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Phase 1.|
EMD 1214063 inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with EMD 1214063 induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. EMD 1214063 effectively blocka phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM. EMD 1214063 considerably inhibits the viability of MKN-45 cells with IC50 of less than 1 nM. Treatment with EMD 1214063 (as low as 0.1 nM) inhibits HGF-induced NCI-H441 cell migration, whereas concentrations of 100 nM to 1 μM almost completely prevents it. 
|In vivo||EMD 1214063 treatment, at doses of 10 mg/kg or more, results in more than 90% inhibition of c-Met phosphorylation in Hs746T xenograft tumor for a period of at least 72 hours. EMD 1214063 induces more than 50% reduction of cyclin D1 expression, which persists after 96 hours upon treatment with doses of 100 mg/kg. A transient induction of p27 and cleaved caspase-3 are also observed upon treatment with EMD 1214063. EMD 1214063 (15 mg/kg, daily) treatment induces complete regression of gastric carcinoma xenografts Hs746T, in which c-Met is amplified, overexpressed, and activated in a ligand-independent fashion. |
|In vitro||DMSO||5 mg/mL warmed (10.15 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03940703||Not yet recruiting||Drug: Tepotinib|Drug: Osimertinib||Non-small Cell Lung Cancer||EMD Serono Research & Development Institute Inc.|Merck KGaA Darmstadt Germany|EMD Serono||July 18 2019||Phase 2|
|NCT03629223||Completed||Drug: Tepotinib TF2|Drug: Tepotinib TF3||Healthy||Merck KGaA Darmstadt Germany||August 23 2018||Phase 1|
|NCT03546608||Completed||Drug: Tepotinib||Hepatic Impairment||EMD Serono Research & Development Institute Inc.|Merck KGaA Darmstadt Germany|EMD Serono||June 13 2018||Phase 1|
|NCT03531762||Completed||Drug: Tepotinib|Drug: Omeprazole||Healthy||Merck KGaA Darmstadt Germany||May 14 2018||Phase 1|
|NCT02115373||Completed||Drug: Tepotinib||Carcinoma Hepatocellular||Merck KGaA Darmstadt Germany||May 18 2014||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.